Morepen Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 12, 2025.
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited consolidated and standalone financial results for Q4 and FY25. On a consolidated basis, total income grew to Rs. 1,82,994 lakhs (vs Rs. 1,70,440 lakhs in FY24) and net profit rose to Rs. 11,802 lakhs (vs Rs. 9,662 lakhs), with EPS at Rs. 2.20. A final dividend of Rs. 0.20 per share (face value Rs. 2) was recommended, subject to shareholder approval. The board signed an addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited (formerly Morepen Medtech), revising the appointed date for hiving off the Medical Devices business on slump sale basis from February 1, 2025 to April 1, 2025. The subsidiary also plans to set up a wholly-owned step-down subsidiary in Dubai, UAE, to expand B2B and B2C medical device business. Additionally, Dr. Morepen (subsidiary) acquired 80% in Quick Med Private Limited, making it a step-down subsidiary.
FY25 shows healthy profit growth on a consolidated basis despite a dip on a standalone level, and the small dividend signals confidence in cash flows. The hive-off of the medical devices business to a subsidiary restructures the company into a focused pharma entity, which could be a precursor to unlocking value or a future demerger/listco plan, while the Dubai expansion opens a new international growth channel.